Beijing Tiantan Biological Products Co., Ltd. (SHA:600161)

China flag China · Delayed Price · Currency is CNY
19.09
-0.05 (-0.26%)
Oct 24, 2025, 3:00 PM CST
-0.26%
Market Cap37.75B
Revenue (ttm)6.42B
Net Income (ttm)1.32B
Shares Out1.98B
EPS (ttm)0.66
PE Ratio28.94
Forward PE22.86
Dividend0.15 (0.79%)
Ex-Dividend DateSep 25, 2025
Volume6,811,009
Average Volume9,206,419
Open19.14
Previous Close19.14
Day's Range19.06 - 19.19
52-Week Range18.86 - 23.61
Beta0.36
RSI40.35
Earnings DateOct 25, 2025

About SHA:600161

Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and marketing of blood products in China and internationlly. Its products include human albumin; intravenous human immunoglobulin; rabies patient immunoglobulin; tetanus human immunoglobulin; hepatitis B human immunoglobulin; freeze-dried intravenous hepatitis B human immunoglobulin; histamine human immunoglobulin; human prothrombin complex; human coagulation factors VIII; human fibrinogen; recombinant human coagulation factor VIII for inje... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1966
Employees 5,298
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600161
Full Company Profile

Financial Performance

In 2024, SHA:600161's revenue was 6.03 billion, an increase of 16.44% compared to the previous year's 5.18 billion. Earnings were 1.55 billion, an increase of 39.58%.

Financial Statements

News

There is no news available yet.